Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stockholders tender their shares Transaction expected

#LSTA Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

www.stocktitan.net/news/LSTA/lisata-therape...

Investigating Fair Deals for RAPT, ALGT, LSTA, and AVO Shareholders Amid Market Concerns Halper Sadeh LLC is probing possible federal securities law violations by RAPT, ALGT, LSTA, and AVO, seeking to protect shareholder interests and ensure fair transactions.

Investigating Fair Deals for RAPT, ALGT, LSTA, and AVO Shareholders Amid Market Concerns #USA #New_York #ALGT #RAPT #LSTA

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer Lisata Therapeutics (Nasdaq: LSTA) entered a binding term sheet to be acquired by Kuva Labs in an all-cash tender offer of $4.00 per share. Stockholders will also receive two non-tradeable contingent value rights (CVRs) worth $1.00 each payable upon (1) reversion of certain Greater China rights and (2) Kuva filing an NDA or similar registration for certepetide.The boards of both companies approved the term sheet unanimously and expect a definitive purchase agreement prior to February 27, 2026. The cash offer is an approximate 85% premium to the most recent close and, including both CVRs, an approximate 180% premium.

#LSTA Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Data rich period continues to support certepetide’s broad applicability and effectiveness Catalent enters into global license agreement for the use of certepetide as part of their SMARTag® Antibody-Drug Conjugate Technology Platform Strategic Alliance formed with GATC Health to exploit their

#LSTA Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent Lisata Therapeutics (Nasdaq: LSTA) highlighted positive preclinical results on November 4, 2025 after Catalent presented data at the 16th Annual World ADC San Diego Conference (Nov 3–6, 2025).Catalent reported that incorporating Lisata’s proprietary iRGD cyclic peptide certepetide as a non-cytotoxic payload in its SMARTag® ADC platform improved tumor-selective penetration and broadened intratumoral distribution of cytotoxic payloads, and also enhanced ADC efficacy in preclinical models. Lisata emphasized this finding as supportive of its licensing partnership with Catalent and its strategy to use certepetide to boost therapeutic delivery across modalities.

#LSTA Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement Lisata Therapeutics (Nasdaq: LSTA) and Catalent announced on October 8, 2025 a global, non-exclusive license allowing Catalent to incorporate Lisata’s certepetide and analogs into ADCs developed with Catalent’s SMARTag® platform.Catalent gains worldwide rights to evaluate certepetide as SMARTag® payloads across multiple ADCs and may partner third parties. Lisata is eligible for over $10 million in tiered study-initiation milestone payments plus revenue sharing on future sales and partnerships. Catalent’s preclinical data provide proof-of-concept that iRGD peptides can improve ADC efficacy and pharmacokinetics; related preclinical work will be highlighted at the November World ADC conference in San Diego.

#LSTA Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial Lisata Therapeutics (Nasdaq: LSTA) reported encouraging preliminary results from the pancreatic cancer (PDAC) cohort of its Phase 1/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies. The trial, led by Dr. Anup Kasi at KU Cancer Center, showed promising outcomes in treating resectable and borderline resectable PDAC.Key findings from the 35-patient PDAC cohort include: 50% R0 resection rate and 70% pathologic partial response among the 10 patients who completed pre-surgical therapy. The study demonstrated a 60% two-year overall survival rate and 12-month median disease-free survival. Importantly, the combination therapy showed enhanced immune cell infiltration and increased expression of immune markers, suggesting potential transformation of pancreatic tumors from "immune-cold" to "immune-hot."

#LSTA Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

www.stocktitan.net/news/LSTA/lisata-therape...

This is good news indeed, and I'm thrilled that cooler heads have prevailed. Keep paying attention to @heykellyjensen.bsky.social on this. #IMLS #LSTA #GrantsToStates

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Lisata Therapeutics (NASDAQ:LSTA) reported Q2 2025 financial results and provided updates on its clinical development portfolio. The company's lead candidate certepetide showed positive preliminary results in multiple clinical trials for advanced solid tumors. Key financial metrics include $22.0 million in cash and equivalents, with runway extending into Q4 2026.Notable developments include positive preliminary data from the ASCEND trial for pancreatic cancer and the iLSTA trial. The company reported Q2 2025 revenue of $70,000 and reduced operating expenses to $4.9 million, down 10.6% year-over-year. A new USPTO patent extends certepetide's protection until March 2040.

#LSTA Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LSTA/lisata-therape...

Breakthrough Pancreatic Cancer Trial Achieves 100% Disease Control Rate with Novel Drug Combination New clinical data reveals promising 60% response rate in advanced pancreatic cancer. Novel drug combination shows complete disease control in Phase 1b/2a trial. See full results.

#LSTA Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

www.stocktitan.net/news/LSTA/lisata-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stock with strong volume gains, Tue Jul 15th- #LSTA #KZR #IKNA #HTOO #DXPE #CMBM #CELU #BWEN #ADAG #ZKIN #XAGE #UCL #RAPT #MSGM #MNY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Lisata's Cancer Drug Secures Strongest Patent Protection, Blocks Competitors Until 2040 New composition of matter patent grants Lisata exclusive rights for cancer drug certepetide, blocking generic competition through 2040. See market impact details.

#LSTA Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development Lisata Therapeutics (NASDAQ: LSTA) and GATC Health Corp. have expanded their strategic alliance to enhance drug discovery and development using AI technology. The partnership combines Lisata's drug development expertise with GATC's Multiomics Advanced Technology (MAT) platform. A key focus is advancing GATC's AI-discovered therapeutic for opioid use disorder (OUD) into Phase 1 human trials in early 2026. The MAT platform, validated by UC Irvine with 86% sensitivity and 91% specificity, will help identify new combination therapies and predict safety and efficacy. GATC will cover R&D costs while Lisata receives milestone fees and royalties from commercialized products. The collaboration aims to accelerate drug development, potentially reducing discovery time from 5-6 years to one year and creating up to $400 billion in value for the pharmaceutical industry by end-2025.

#LSTA Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Lisata Therapeutics (NASDAQ: LSTA) reported Q1 2025 financial results and provided updates on its clinical development portfolio. The company's lead drug certepetide showed encouraging results in multiple trials, including positive trends in the ASCEND trial's Cohort A for pancreatic cancer treatment. Key financial metrics show net losses of $4.7 million for Q1 2025, down from $5.4 million in Q1 2024, with cash reserves of $25.8 million expected to fund operations into Q3 2026. Operating expenses decreased 11.4% to $5.8 million. The company is advancing multiple clinical trials, including ASCEND, BOLSTER, CENDIFOX, and iLSTA, across various solid tumor types. Notably, Cohort B results from the ASCEND trial have been accepted for oral presentation at ESMO-GI 2025, and the company maintains strategic partnerships with Qilu Pharmaceutical, Catalent, and other organizations.

#LSTA Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LSTA/lisata-therape...

Game-Changing Cancer Treatment Alliance: Lisata and Catalent Combine Breakthrough Technologies Strategic partnership combines certepetide with SMARTag® ADC platform to enhance solid tumor treatment. Catalent funds R&D with upfront payment to Lisata.

#LSTA Lisata Therapeutics Announces Research License with Catalent

www.stocktitan.net/news/LSTA/lisata-therape...

Can AI Revolutionize Lisata's Pancreatic Cancer Drug? New GATC Health Partnership Aims to Prove It Lisata teams with GATC Health to leverage AI for optimizing certepetide's Phase 3 trials for pancreatic cancer while exploring new indications and drug combinations.

#LSTA Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Lisata Therapeutics (NASDAQ: LSTA) has reported its full year 2024 financial results and provided updates on its development portfolio. The company's primary focus is on certepetide, a novel treatment for advanced solid tumors. Key highlights include promising preliminary Phase 2b (ASCEND) pancreatic cancer data from Cohort A, with Cohort B data expected in coming months.Financial results show revenue of $1.0 million from a Kuva Labs licensing agreement, while operating expenses decreased 8.9% to $23.4 million. Net losses were $20.0 million for 2024, compared to $20.8 million in 2023. The company maintains a strong financial position with $31.2 million in cash and equivalents, providing runway into Q2 2026.Multiple clinical trials are advancing, including ASCEND, BOLSTER, CENDIFOX, and iLSTA, evaluating certepetide across various cancer types. The company received $0.9 million in non-dilutive funding through New Jersey's Tax Certificate Transfer Program.

#LSTA Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/LSTA/lisata-therape...

NEWS: ( NASDAQ: #LSTA ) Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

#StockMarket #News

Lisata Therapeutics Hits Major Milestone in Cancer Trial: Full Enrollment Complete for CENDIFOX Study Lisata achieves full patient enrollment in Phase 1b/2a CENDIFOX trial, testing certepetide combination therapy across pancreatic, colon & appendiceal cancers. Results due 2025.

#LSTA Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

#StockMarket #news #investing

www.stocktitan.net/news/LSTA/lisata-therape...

Lisata Therapeutics Partners with Kuva Labs for Breakthrough Cancer Imaging Technology | LSTA Stock News Lisata Therapeutics licenses certepetide to Kuva Labs for advanced MRI cancer diagnostics, securing upfront fees and future royalties in major collaboration deal.

#LSTA Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

#investing #stocks #StockMarket

www.stocktitan.net/news/LSTA/lisata-therape...